Health

Change opioid prescribing guidance, U.S. lawmakers ask WHO

World Health Organization asked to withdraw pain care guidelines that U.S. lawmakers say made false claims about safety.

Other countries could face the same kind of addiction and overdose crisis that's plagued the U.S.

In this 2018 photo, family and friends who have lost loved ones to OxyContin and opioid overdoses leave pill bottles in protest. Purdue and other drugmakers face lawsuits from state, local and tribal governments across the U.S. seeking to hold them accountable for the crisis. (Jessica Hill/Associated Press)

Two U.S. lawmakers are calling on the World Health Organization to withdraw pain care guidelines that include what they say are false claims about the safety of prescription opioids.

They say the guidelines could lead other countries toward the same kind of addiction and overdose crisis that has plagued the U.S. in recent years.

The members of Congress say a 2011 manual and 2012 guidelines on opioids were influenced by people with financial connections to Purdue Pharma, the company that makes the powerful opioid painkiller OxyContin.

"We have come to believe that Purdue has leveraged its financial ties to successfully impact the content of the WHO's guidelines," Representatives Katherine Clark, a Massachusetts Democrat, and Hal Rogers, a Kentucky Republican, say in a letter to the health arm of the United Nations. "As a result, the WHO is, in effect, promoting the chronic use of opioids."

Clark said the report was put together because the WHO did not change its guidelines after a 2017 letter from her, Rogers and other members of Congress raised concerns that Purdue's international arm was aggressively marketing opioids abroad.

"We have received the most recent letter from Congress and are reviewing it point by point," WHO spokesman Christian Lindmeier said in an email Wednesday.

Purdue, which operates in the U.S., called the report an attempt to "vilify" the company and noted that the U.S. Food and Drug Administration has approved OxyContin as safe and effective for treating chronic pain. "Purdue is deeply concerned about the impact of opioid abuse and addiction and we remain committed to simultaneously supporting efforts that help pain patients in need and create real solutions to this public health crisis," the company said in a statement.

The company also says it discloses any potential conflicts of interest.

A spokeswoman for Mundipharma, an international drug company owned by the Sackler family, which also owns Stamford, Connecticut-based Purdue, said the company would not comment on the report. A spokesman for several members of the Sackler family also did not comment.

Opioids, a class of drugs that includes prescription painkillers as well as heroin and fentanyl, has become the leading cause of accidental death in the U.S. in recent years and were linked to more than 390,000 deaths in the U.S. between 2000 and 2017.

According to Health Canada, 10,337 people were killed by opioid-related drug overdoses between Jan. 2016 and Sept. 2018.

Purdue and other drugmakers and distributors are facing about 2,000 lawsuits from state, local and tribal governments across the U.S. seeking to hold them accountable for the crisis. The suits claim Purdue aggressively promoted use of its drugs on more patients and at higher doses while downplaying the addiction risks. They also say the company pushed to have the drugs used for chronic pain when they traditionally had been used mostly for acute pain, such as after surgeries, or for pain from cancer or other terminal conditions.

The members of Congress say the company has tried to do the same thing around the world.

"It's the exact same strategies and it is infuriating and terrifying to see the World Health Organizations having incorporated these strategies," Clark said in an interview Wednesday.

With files from CBC News

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.